The CYP11B2 gene¹¹ CYP11B2 gene
encodes aldosterone synthase, the enzyme catalyzing the final three steps of aldosterone biosynthesis in the adrenal cortex. Aldosterone is the body's primary mineralocorticoid hormone — it controls sodium retention, potassium excretion, and blood pressure by acting on the kidneys' collecting ducts. The rs1799998 variant (-344C>T) sits in the promoter region of CYP11B2 at a binding site for steroidogenic factor-1 (SF-1)²² steroidogenic factor-1 (SF-1)
a transcription factor that drives expression of steroid-synthesizing enzymes including CYP11B2. Depending on which allele you carry, your adrenal glands may be genetically primed to produce more aldosterone throughout your life.

Important note on allele notation: Published literature uses coding-strand notation (C and T alleles). Because CYP11B2 is on the minus strand, genome files report the complementary plus-strand alleles: A corresponds to the T allele described in papers (the higher-expression allele), and G corresponds to the C allele. All genotypes in this profile use plus-strand notation.

The Mechanism

The -344 position in the CYP11B2 promoter sits within the SF-1 binding site³³ SF-1 binding site
SF-1, encoded by NR5A1, is a master regulator of adrenal steroidogenic gene expression. The T allele (A on plus strand) alters the binding affinity of this site, shifting the regulatory landscape toward enhanced transcriptional output.

CYP11B2 exists within a haplotype block containing three linked promoter variants. The haplotype containing -344T (haplotype-I) shows measurably greater CYP11B2 expression — demonstrated in transgenic mice carrying the human gene with haplotype-I, which produced 2.2-fold higher mRNA in adrenals and 1.54-fold higher expression in kidneys compared to haplotype-II (-344C) mice. Critically, haplotype-I mice developed a 7 mmHg higher baseline blood pressure, and under high-salt diet, failed to appropriately suppress aldosterone — driving further blood pressure elevation — while haplotype-II mice showed normal salt-induced RAAS suppression.

The Evidence

In a multi-ethnic study of 1,313 participants, the TT genotype was associated with 14% higher plasma aldosterone levels and 3.7 mmHg higher systolic / 2.1 mmHg higher diastolic blood pressure compared to CC carriers⁴⁴ the TT genotype was associated with 14% higher plasma aldosterone levels and 3.7 mmHg higher systolic / 2.1 mmHg higher diastolic blood pressure compared to CC carriers, after adjustment for age, sex, and ethnicity. The T allele was also over-represented in individuals with elevated aldosterone-to-renin ratios.

In an Egyptian cohort, the T allele was significantly more frequent in hypertensive patients (OR 2.51; 95% CI 1.3–3.5; P=0.002)⁵⁵ the T allele was significantly more frequent in hypertensive patients (OR 2.51; 95% CI 1.3–3.5; P=0.002). The TT genotype was specifically associated with greater left ventricular mass index (LVMI), suggesting that the elevated aldosterone drives not just blood pressure but also cardiac remodeling.

For cardiac structure, the -344 C/T polymorphism is associated with left ventricular structure in arterial hypertension⁶⁶ the -344 C/T polymorphism is associated with left ventricular structure in arterial hypertension, with different patterns by genotype: CC carriers tend toward eccentric LVH, while a strong correlation between LV mass and urinary sodium excretion was observed specifically in CC and intron-2-conversion carriers⁷⁷ CC and intron-2-conversion carriers, suggesting the sodium-LV mass link operates through different mechanisms by genotype.

The SILVHIA trial found a striking pharmacogenomic signal: TT carriers showed -21 mmHg systolic BP reduction with irbesartan, versus 0 mmHg for CC carriers⁸⁸ TT carriers showed -21 mmHg systolic BP reduction with irbesartan, versus 0 mmHg for CC carriers, suggesting the T allele's excess aldosterone production creates greater suppressibility by AT1 receptor blockade. A Chinese study found CC+CT carriers responded better to valsartan (4.7 mmHg greater SBP reduction), illustrating that drug-response findings vary by population.

One large multi-ethnic U.S. study (n=3,452) found no association with blood pressure, plasma aldosterone, or LV mass⁹⁹ found no association with blood pressure, plasma aldosterone, or LV mass, highlighting genuine heterogeneity in the literature — likely driven by differences in dietary sodium, comorbidities, population genetic backgrounds, and LD patterns.

Practical Actions

The most actionable implication of the -344T/A genotype is salt sensitivity of blood pressure. Even without confirmed hypertension, carriers of one or two A alleles (particularly AA homozygotes) have a biological predisposition toward aldosterone-mediated sodium retention. Reducing dietary sodium blunts the aldosterone-driven pathway at its source.

If you have hypertension and carry the AA genotype, AT1 receptor blockers (irbesartan, valsartan) may offer superior blood pressure reduction by blocking the downstream effects of elevated aldosterone. Discuss this pharmacogenomic data with your physician when selecting antihypertensive therapy.

Interactions

CYP11B2 rs1799998 functions within the renin-angiotensin-aldosterone system (RAAS) pathway alongside AGTR1 rs5186 (A1166C), which affects angiotensin II receptor expression, and AGT rs699 (M268T), which influences angiotensinogen levels. Published studies have found interactive effects between CYP11B2 -344T and ACE insertion/deletion on atrial fibrillation risk and T2DM susceptibility. Individuals carrying multiple RAAS-sensitizing variants across CYP11B2, AGTR1, and AGT may have additive blood pressure effects beyond any single variant, with the CYP11B2 AA + AGTR1 CC combination representing the highest sodium-sensitive hypertension burden within this pathway.

Von Willebrand factor¹¹ Von Willebrand factor
a large multimeric glycoprotein produced by endothelial cells and megakaryocytes; acts as the primary platelet adhesion bridge at sites of vascular injury and as the plasma carrier that protects coagulation factor VIII from premature degradation is arguably the single most important quantitative determinant of bleeding and thrombosis risk below the level of frank coagulation factor deficiency. Normal-range plasma VWF antigen levels span roughly 50–200 IU/dL — a four-fold window — and that variation is substantially heritable. The rs1800380 variant falls within a 50-kilobase stretch of the VWF gene that has the strongest known cis-acting influence on circulating VWF concentrations in people of European and African descent.

The Mechanism

rs1800380 is a synonymous C>T substitution in VWF exon 22 (c.2880G>A; NM_000552.5) that does not change the encoded amino acid — both the C and T alleles produce arginine at codon 960. The T allele is on the GRCh38 plus strand; the VWF gene is on the minus strand, so this corresponds to a c.2880G>A coding-strand change (G→A) that is silent at the protein level. Yet the variant strongly associates with plasma VWF antigen levels across independent populations.

The likely explanation is that rs1800380 itself is not the causative change but rather a tag SNP²² tag SNP
a variant in strong linkage disequilibrium with the true functional variant, allowing it to serve as a reliable proxy for the causal haplotype in GWAS. It sits within haplotype block 5³³ haplotype block 5
a 50-kb stretch of the VWF gene encoding the D2, D', and D3 domains that regulate VWF multimerization, packaging into Weibel-Palade bodies, and regulated secretion into the circulation. The T allele marks the high-VWF haplotype in this block. The causal variant — likely within the same block — may alter VWF mRNA secondary structure, splicing efficiency, transcription factor binding, or protein folding in the secretory pathway.

The effect of the T allele is additive: each copy adds approximately +0.03 units (log-scale) to circulating VWF:Ag after adjustment for ABO blood group, and the p-value for this association is 4.4×10⁻⁹ post-ABO adjustment in the ARIC cohort (n=7,856). This level of evidence is genome-wide significant and replicates across European and African-descent populations.

The Evidence

The definitive mapping of rs1800380 to VWF antigen levels comes from the ARIC cohort target-gene analysis⁴⁴ ARIC cohort target-gene analysis
Campos et al. Blood 2011, 7,856 European-descent subjects, 78 VWF SNPs analyzed. Of 18 SNPs significantly associated with VWF:Ag in this dataset, rs1800380 was one of only two in actual exonic positions (the other being rs1063857 in exon 18). The pre-ABO p-value was 1.6×10⁻⁷; after ABO adjustment the signal strengthened to 4.4×10⁻⁹, confirming that the haplotype's VWF-raising effect is mechanistically independent of blood-group-mediated VWF clearance. The 15 significant block-5 and block-6 SNPs form two distinct haplotypes that together explain a substantially larger fraction of within-gene VWF level variance than any single SNP alone.

The downstream clinical consequence of elevated VWF is well established. A transethnic GWAS meta-analysis by Sabater-Lleal et al. 2019⁵⁵ Sabater-Lleal et al. 2019 used Mendelian randomization to demonstrate a causal relationship between plasma VWF levels and ischemic stroke risk — meaning that genetically elevated VWF is not merely a marker of vascular inflammation but a driver of thrombotic events. This finding upgrades the clinical relevance of VWF-raising variants from "associated with higher biomarker" to "causally linked to stroke," at least at the population level.

Plasma VWF levels above 150 IU/dL are associated with 2–3× increased risk of venous thromboembolism in longitudinal studies (Vischer 2011)⁶⁶ (Vischer 2011). The VWF-raising haplotype tagged by rs1800380 T shifts baseline VWF in the direction of this elevated-risk zone, particularly in non-O blood group individuals (who already have slower VWF clearance due to O-type glycan differences).

In the Rotterdam Study's promoter analysis (de Lange et al. 2004)⁷⁷ (de Lange et al. 2004), a promoter haplotype associated with higher VWF levels showed a 2.6-fold increased coronary heart disease risk in subjects with advanced atherosclerosis — illustrating how the VWF-raising effect becomes most clinically relevant in the setting of other vascular risk factors.

The evidence level is strong: the rs1800380 T allele association with VWF:Ag levels reaches genome-wide significance, replicates across ancestries, and the downstream cardiovascular consequences of elevated VWF have causal support from Mendelian randomization. The individual effect size is modest (explaining <1% of VWF variance on its own), and the haplotype context means the variant's specific contribution cannot be fully disentangled from neighboring SNPs without fine-mapping.

Practical Actions

For TT homozygotes carrying two copies of the high-VWF haplotype tag, the priority is knowing whether your circulating VWF:Ag is actually elevated — only a blood test can confirm this. Levels persistently above 150 IU/dL (particularly in non-O blood group individuals) warrant proactive monitoring and risk factor management. The pro-thrombotic risk is most relevant in specific, high-stakes contexts: prolonged immobility, major surgery, use of estrogen-containing contraceptives, or concurrent inherited thrombophilia.

CT heterozygotes have intermediate VWF levels and a proportionally intermediate risk profile; measurement is useful if other thrombotic risk factors are present.

CC homozygotes carry the lower-VWF haplotype and have no elevation-specific action items; their VWF levels are in the population-normal to low-normal range for this variant.

Interactions

ABO blood group is the dominant modifier of plasma VWF levels in all populations, accounting for ~15% of VWF antigen variance via glycan-mediated differences in clearance rate. Non-O individuals with the T allele haplotype will show the largest VWF elevations — the high-expression haplotype (tagged by T) combined with non-O blood group (slower VWF clearance) acts in the same direction, compounding VWF elevation above either factor alone.

Among VWF coding variants, rs216311 (Thr1381Ala, exon 28) independently raises VWF levels through a structural mechanism in the D4 domain. Carriers of both the rs1800380 T haplotype and the rs216311 C allele (Ala) will have the highest within-gene VWF levels. The ADAMTS13 substrate-cleavage variants in this category (rs28647808, rs2288904) operate through a complementary VWF-processing pathway: reduced ADAMTS13-mediated VWF cleavage amplifies whatever VWF is being secreted, so high secretion (rs1800380 T haplotype) combined with reduced cleavage (ADAMTS13 variants) further elevates ultra-large VWF multimers.

The HFE gene encodes the hereditary hemochromatosis protein¹¹ hereditary hemochromatosis protein
A membrane protein structurally similar to MHC class I molecules that regulates iron absorption by sensing blood iron levels and modulating hepcidin expression, a key regulator of iron homeostasis. A single G-to-A change at nucleotide 845 replaces cysteine with tyrosine at position 282 of the protein, destroying a critical disulfide bond in the alpha-3 domain²² alpha-3 domain
The immunoglobulin-like C1-set domain that mediates binding to beta-2 microglobulin, essential for proper protein folding and cell surface expression. This variant — universally known as C282Y — is the primary cause of hereditary hemochromatosis type 1, the most common autosomal recessive condition in people of European descent.

The Mechanism

HFE normally forms a complex with beta-2 microglobulin³³ beta-2 microglobulin
A small protein that stabilizes MHC class I and class I-like molecules, enabling their transport to the cell surface and travels to the cell surface, where it interacts with transferrin receptors (TfR1 and TfR2) to sense circulating iron levels. When iron is sufficient, this signaling cascade stimulates the liver to produce hepcidin⁴⁴ hepcidin
The master iron-regulatory hormone; it blocks ferroportin, the only known cellular iron exporter, thereby reducing iron absorption from the gut and iron release from macrophages, which in turn blocks iron absorption from the intestine by degrading ferroportin⁵⁵ ferroportin
The sole known iron export channel on intestinal epithelial cells and macrophages on gut cells.

The C282Y mutation prevents HFE from binding beta-2 microglobulin. Without this partner, the protein cannot fold correctly, never reaches the cell surface, and accumulates uselessly inside the cell. The result is a broken iron sensor: the liver produces inappropriately low hepcidin regardless of how much iron is already in the body. With the brake removed, the gut absorbs 2-3 times more dietary iron than normal, and macrophages release stored iron unchecked. Over decades, this excess iron deposits in the liver, heart, pancreas, and joints.

The Evidence

The landmark 1996 discovery⁶⁶ landmark 1996 discovery
Feder JN et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet, 1996 by Feder and colleagues identified the HFE gene and found C282Y homozygosity in 83% of hereditary hemochromatosis patients. This remains the most common genetic cause of iron overload worldwide.

The Melbourne Collaborative Cohort Study⁷⁷ Melbourne Collaborative Cohort Study
Allen KJ et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med, 2008 followed 31,192 persons of European descent for 12 years. Among 203 C282Y homozygotes, iron-overload-related disease developed in 28.4% of men but only 1.2% of women — highlighting the dramatic sex difference in clinical penetrance. Men are far more vulnerable because they lack the protective iron losses from menstruation.

A UK Biobank analysis⁸⁸ UK Biobank analysis
Pilling LC et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ, 2019 of 451,243 participants confirmed that C282Y homozygous men have significantly higher rates of liver disease (HR 2.22), diabetes (HR 1.72), and arthritis compared with non-carriers. Hemochromatosis was diagnosed in 21.7% of homozygous men by end of follow-up.

A meta-analysis of 43 study populations⁹⁹ meta-analysis of 43 study populations
Bacon BR et al. Hemochromatosis genotypes and risk of iron overload — a meta-analysis. Genet Med, 2011 pooling 9,986 cases and 25,492 controls established C282Y homozygosity as the overwhelmingly dominant genetic risk factor for both biochemical and clinical iron overload.

Practical Implications

For AA (C282Y homozygous) individuals: you carry the highest-risk genotype for hereditary hemochromatosis. Regular serum ferritin and transferrin saturation monitoring is essential. If iron levels are elevated, therapeutic phlebotomy (regular blood removal) is the standard treatment and is highly effective when started before organ damage occurs. Limit iron-fortified foods and high-dose vitamin C supplements, which enhance iron absorption. Avoid excess red meat and iron-containing multivitamins.

For AG (heterozygous carrier) individuals: you carry one copy of C282Y. Your iron levels may run slightly higher than average, which is generally benign and may even protect against iron deficiency anemia. Routine ferritin screening every few years is reasonable. Significant iron overload from heterozygosity alone is rare.

For GG (wild-type) individuals: you have normal HFE function at this locus. Standard dietary iron recommendations apply.

Interactions

The most clinically significant interaction is with H63D (rs1799945)¹⁰¹⁰ H63D (rs1799945)
HFE H63D is a milder variant in the same gene; compound heterozygosity (one C282Y + one H63D) confers a small risk of mild iron overload in the same gene. Compound heterozygosity — carrying one C282Y allele and one H63D allele — produces a mildly elevated risk of iron overload, though far less than C282Y homozygosity. A study of compound heterozygotes¹¹¹¹ study of compound heterozygotes
Walsh A et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology, 2009 found that documented iron-overload-related disease occurred in only about 1-2% of C282Y/H63D compound heterozygotes, similar to wild-type rates. However, mean serum ferritin and transferrin saturation were significantly elevated compared with non-carriers, so monitoring remains reasonable.

If a user carries C282Y heterozygous (AG at rs1800562) plus H63D heterozygous (CG at rs1799945), a compound implication should advise periodic ferritin monitoring, as the combination slightly amplifies iron absorption beyond either variant alone. This interaction is well-documented but low-penetrance.

The TNF gene encodes tumor necrosis factor-alpha¹¹ tumor necrosis factor-alpha
a master regulator of inflammation and immune response, produced by macrophages, T cells, and other immune cells. This -308 G>A variant sits in the promoter region²² promoter region
the DNA sequence that controls how much TNF-alpha gets made of the gene on chromosome 6p21.3, within the major histocompatibility complex. The A allele disrupts transcription factor binding sites and increases TNF-alpha production approximately 2-fold compared to the G allele when immune cells are stimulated.

The Mechanism

This is a regulatory variant that affects gene transcription³³ affects gene transcription
how much protein gets made from the gene. The -308 position is 308 base pairs upstream of where the TNF gene starts being copied into RNA. The A allele alters binding sites for nuclear transcription factors, leading to enhanced transcriptional activity in immune cells. When your immune system encounters a threat, carriers of the A allele produce substantially more TNF-alpha than GG carriers, amplifying the inflammatory response.

The Evidence

A meta-analysis of 1,774 controls and 1,147 celiac disease cases found the A allele confers a 2-fold increased risk (OR 2.051) , with

AA homozygotes showing 6.6-fold increased risk (OR 6.626) .

The A allele leads to approximately 2-fold higher TNF-alpha transcription upon immune cell stimulation , and carriers show significantly higher serum TNF-alpha levels .

The variant also predicts response to anti-TNF biologic drugs⁴⁴ anti-TNF biologic drugs
medications like infliximab and etanercept that block TNF-alpha used to treat rheumatoid arthritis and inflammatory bowel disease.

RA patients carrying the GG genotype are better responders to etanercept, while the AA genotype significantly decreases response .

The same pattern holds for etanercept—GG shows better response than AA or AG .

Associations have been reported with multiple autoimmune conditions.

In rheumatoid arthritis patients, A allele carriers show higher risk of cardiovascular events (HR 1.72), particularly in those also carrying the rheumatoid shared epitope . Studies link the variant to increased risk of vitiligo, preeclampsia in Asian and Caucasian populations, and aggressive periodontitis.

Practical Implications

If you have autoimmune disease, particularly rheumatoid arthritis or inflammatory bowel disease, your -308 genotype may influence how well you respond to anti-TNF biologic medications. GG carriers tend to respond better to anti-TNF drugs like etanercept (Enbrel), while A allele carriers may need alternative mechanisms. If you're an A allele carrier who doesn't respond well to one anti-TNF drug, switching to a different mechanism of action (like IL-6 inhibitors or JAK inhibitors) may be more effective than trying another anti-TNF.

For those with one or two A alleles, the A allele doesn't cause inflammation by itself—it amplifies your body's inflammatory response when triggered. This means known inflammatory triggers may provoke stronger responses in A allele carriers, and autoimmune flares may be more intense.

Interactions

The TNF-308 variant sits within a cluster of related TNF polymorphisms including rs361525⁵⁵ rs361525
TNF-238 G>A, another promoter variant and rs1799724⁶⁶ rs1799724
TNF-857 C>T. These variants are in linkage disequilibrium, meaning they're often inherited together. Compound effects with other inflammatory pathway genes (IL-6, IL-10, IL-1) have been documented, particularly for predicting anti-TNF drug response.

Plasma fibrinogen is both the raw material for blood clots and a sensitive index of systemic inflammation. Every 1 g/L increase in fibrinogen¹¹ Every 1 g/L increase in fibrinogen
Fibrinogen is synthesized in the liver and circulates at 2-4 g/L; levels rise during the acute-phase response to infection, surgery, or chronic low-grade inflammation doubles the hazard for coronary heart disease and nearly doubles it for ischemic stroke across 154,211 participants in the Fibrinogen Studies Collaboration. The rs1800788 variant — a G-to-A substitution 854 base pairs upstream of the FGB transcription start site, appearing as C>T on the genomic plus strand — sits within one of the three truly functional regulatory nodes of the beta-fibrinogen promoter. The T allele at this position (corresponding to the -854A allele in older literature) increases transcriptional output, raising the constitutive fibrinogen set point and amplifying the inflammatory surge when IL-6 signaling rises.

The Mechanism

The FGB gene on chromosome 4q31 encodes the beta chain of fibrinogen. Its promoter region contains multiple binding sites for transcription factors activated by interleukin-6 (IL-6)²² interleukin-6 (IL-6)
The primary hepatic acute-phase cytokine; released during infection, surgery, metabolic stress, or chronic inflammation; directly drives FGB transcription in hepatocytes, the master cytokine that signals the liver to ramp up acute-phase protein production.

Transfection studies in HepG2 liver cells by van 't Hooft et al. 1999³³ van 't Hooft et al. 1999
Van 't Hooft FM et al. Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol. 1999;19(12):3063-70 demonstrated that the -854A allele (T on the plus strand) increases basal transcription by approximately 51% compared to the reference G allele. This is not a passive association — the polymorphism alters the binding landscape for nuclear regulatory proteins at this locus, directly changing how strongly the gene is expressed in liver cells.

Further confirmation of functional status came from Morozumi et al. 2009⁴⁴ Morozumi et al. 2009
Morozumi T et al. The functional effects of the -455G/A polymorphism on the IL-6-induced expression of the beta-fibrinogen gene may be due to linkage disequilibrium with other functional polymorphisms. Immunol Invest. 2009;38(3-4):311-23, who used artificial haplotype constructs to isolate individual site effects. Among three candidate functional polymorphisms (-1420G/A, -854G/A, and -148C/T), the -854A allele significantly raised IL-6-induced promoter activity. This places rs1800788 in a select group of FGB promoter variants with direct experimental evidence of functional consequence, distinct from -455G/A, whose effects may be largely mediated through linkage disequilibrium with these truly functional sites.

The Evidence

The in vitro transcription data are compelling: the -854A allele raises basal FGB promoter output by ~51%. Van 't Hooft et al. showed that plasma fibrinogen levels in healthy middle-aged men were significantly higher in carriers of the rare alleles at both -455G/A and -854G/A, with the two polymorphisms together explaining approximately 11% of plasma fibrinogen variation — a substantial fraction given the many environmental contributors.

Population-level haplotype evidence comes from the HIFMECH study⁵⁵ HIFMECH study
Mannila MN et al. Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe. J Intern Med. 2005;257(3):247-57, a four-centre European case-control investigation. The -854G/A site was included in the haplotype analysis alongside -249C/T and -455G/A. The FGB promoter haplotype block significantly predicted fibrinogen concentration in MI patients (p<0.001, explaining 11.5% of fibrinogen variance); elevated fibrinogen was an independent predictor of MI only in the London cohort (standardized OR=3.58, 95% CI 1.31-9.83), with geographic and environmental modifiers shaping when genetically elevated fibrinogen translates into measurable clinical risk.

The overall fibrinogen-cardiovascular disease relationship provides the quantitative context: the Fibrinogen Studies Collaboration⁶⁶ the Fibrinogen Studies Collaboration
Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality. JAMA. 2005;294(14):1799-809 established hazard ratios of 2.42 per 1 g/L increase for CHD and 2.06 per 1 g/L for stroke, with no threshold — even modest constitutive elevations accumulate risk continuously. When the -854A allele contributes to a persistently higher fibrinogen baseline, each inflammatory episode can push levels into ranges that appreciably increase event probability.

One note on evidence interpretation: an exercise study in 762 male army recruits found no independent effect of -854G/A on exercise-induced fibrinogen elevation after controlling for -455G/A genotype, suggesting the in vivo fibrinogen signal is dominated by the LD haplotype block. The individual contribution of rs1800788 to circulating fibrinogen may therefore be smaller than the in vitro data suggests, and is best understood as part of the FGB promoter haplotype rather than as a fully isolated effect.

Practical Actions

The T allele raises FGB promoter activity at baseline and under IL-6 stimulation. For carriers, the most actionable implication is that plasma fibrinogen should be measured as part of cardiovascular risk profiling — not as a diagnosis, but to determine whether the genetic upregulation has translated into measurable elevation. If fibrinogen is elevated (>3.5-4 g/L), targeted interventions can reduce it: long-chain omega-3 fatty acids (EPA+DHA) lower fibrinogen by 0.2-0.5 g/L in controlled trials — one of the few interventions with documented fibrinogen-lowering efficacy of clinical magnitude.

Tobacco is the strongest environmental amplifier of the FGB promoter: smoking raises fibrinogen by 0.5-1.0 g/L independently, compounding any genetic elevation and dramatically expanding the range of inflammatory insult.

Interactions

rs1800788 sits in a haplotype block with the other major FGB promoter variants: rs1800790 (-455G>A) and rs1800787 (-148C>T). Importantly, the -854G/A site is in negative linkage disequilibrium with -455G/A and -148C/T in Chinese Han populations, meaning the fibrinogen-raising alleles at these sites do not co-occur as frequently as might be expected — the haplotype structure partially distributes risk across these positions. The HIFMECH data identified four major European haplotypes (CGG ~47%, CAG ~20%, TGG ~18%, CGA ~15%), with distinct fibrinogen effects per haplotype. Individuals carrying the -854A (T) allele alongside the -455A or -148T alleles warrant the most aggressive monitoring, as combined haplotype burden on FGB transcription is likely additive. See rs1800790 (-455G>A) and rs1800787 (-148C>T) for the complementary variant profiles.

Interferon-gamma is the immune system's master activator — the cytokine that tells macrophages to destroy intracellular pathogens, drives Th1 polarization¹¹ Th1 polarization
Th1 cells are a subset of helper T cells that specialize in cell-mediated immunity against viruses and bacteria; their hallmark cytokine is interferon-gamma, and keeps chronic inflammatory responses calibrated against genuine threats. rs1861494 is an intronic polymorphism in IFNG that doesn't change the protein but influences how much interferon-gamma gets made. The T allele is associated with higher IFN-γ secretion — which sounds advantageous until the signal doesn't turn off, driving IBD flares, tissue damage, and a paradoxically complex relationship with infectious diseases.

The Mechanism

The IFNG gene sits on the minus strand of chromosome 12 (GRCh38 position 68,157,629). rs1861494 is located in intron 3²² intron 3
Introns are non-coding segments of pre-mRNA that are spliced out before the message is translated into protein; intronic variants can alter RNA splicing, regulatory element binding, or epigenetic marks without changing amino acid sequence, 284 nucleotides downstream of exon 3 (c.366+284). Despite being non-coding, this position overlaps regulatory elements that control IFNG transcription.

The key finding from Gonsky et al. (2014) is that the T allele is associated with altered CpG methylation³³ CpG methylation
DNA methylation at CpG dinucleotides is an epigenetic silencing mechanism; lower methylation at the IFNG promoter typically allows more transcription factor binding and higher IFN-γ output patterns at the IFNG promoter. T allele carriers show a profile associated with greater transcription factor access and higher IFN-γ protein secretion. This regulatory effect propagates from the intronic position through epigenetic remodeling — an intronic variant acting like a dial on cytokine output.

The Evidence

The most clinically informative study comes from inflammatory bowel disease. Gonsky et al. (Inflamm Bowel Dis, 2014, PMID 25171510)⁴⁴ Gonsky et al. (Inflamm Bowel Dis, 2014, PMID 25171510) found that the T allele at rs1861494 associated with measurably higher IFN-γ protein secretion from intestinal tissue. In ulcerative colitis, T allele carriers showed higher levels of anti-neutrophil cytoplasmic autoantibodies (ANCA) and faster progression to colectomy. In Crohn's disease, they were more likely to develop the complicated stricturing/penetrating phenotype — the form requiring surgery. Critically, the study also showed that the methylation changes at the IFNG promoter correlate with T allele carriage, providing a mechanistic link between genotype and elevated cytokine output.

Tuberculosis data are more complex. In a Chinese Han population, Wu et al. (Cytokine, 2019, PMID 31310896)⁵⁵ Wu et al. (Cytokine, 2019, PMID 31310896) found the C allele — not T — associated with TB susceptibility (OR 1.25, P=0.009), with a striking age effect: OR 2.40 in participants under 25. The same group, studying a Tibetan population (PMID 36524496)⁶⁶ (PMID 36524496), found the opposite — CT genotype was protective relative to TT. An Indian cohort (Dhiman et al., Gene 2022, PMID 35248660)⁷⁷ (Dhiman et al., Gene 2022, PMID 35248660) again reversed direction: T allele was the TB susceptibility allele (OR 2.18, P<0.001). This population heterogeneity is common for immune-response genes — the optimal IFN-γ level for clearing Mycobacterium tuberculosis differs by host genetic background, bacterial strain, and pathogen burden. The TB data should not be interpreted as a definitive risk signal in either direction; they illustrate that this variant modulates immune tone in a context-dependent way.

The most consistent finding across studies is the IBD-severity association: higher IFN-γ output in the gut correlates with more aggressive disease, suggesting the T allele tips the Th1/Th2 balance toward chronic mucosal inflammation in susceptible individuals.

Practical Implications

For TT homozygotes, the genetically elevated IFN-γ tone has two practical consequences. First, if you have or are at risk for IBD, this variant suggests your intestinal immune environment is already biased toward Th1-driven inflammation — a consideration for both monitoring and lifestyle decisions. Second, from a treatment standpoint, the IBD paper (PMID 25171510) noted that the T allele may predict better response to anti-TNF biologics⁸⁸ anti-TNF biologics
Drugs like infliximab and adalimumab that block TNF-alpha, a cytokine that works alongside IFN-γ in the Th1 inflammatory cascade; IFN-γ high expressers may have greater TNF-dependent inflammation to suppress, which is clinically useful if treatment decisions arise.

For CT heterozygotes, IFN-γ output sits between the two homozygous states. Intermediate IFN-γ levels often represent the immunologically optimal range — sufficient for pathogen clearance without the inflammatory excess seen in TT carriers.

CC homozygotes, carrying two copies of the lower-expression allele, show a more restrained IFN-γ response. While this is associated with protection against IBD severity, some data suggest it may reduce Th1-mediated clearance of intracellular pathogens in certain population contexts.

Interactions

The most studied IFNG interaction involves the receptor gene IFNGR1, particularly its variants rs2234711 and rs3799488. These receptor variants alter IFN-γ signaling efficiency downstream of the cytokine itself. A high-producing genotype (TT at rs1861494) combined with impaired receptor signaling creates a decoupled system — more cytokine, less effect — while the combination of high production and normal receptor signaling amplifies both beneficial and harmful Th1 effects. rs1861493 (c.366+497) and rs2069718 (c.367-895) are neighboring IFNG intronic variants that have been studied in the same haplotype contexts; the rs1861493-rs1861494 TA haplotype has been associated with tuberculosis susceptibility in north Indian populations.

The CD40 gene encodes a co-stimulatory receptor¹¹ co-stimulatory receptor
CD40 belongs to the TNF receptor superfamily; it is constitutively expressed on B cells, dendritic cells, monocytes, and macrophages that sits at the intersection of innate and adaptive immunity. When CD40 on an antigen-presenting cell binds its ligand CD40L (CD154) on activated T helper cells, it triggers B-cell proliferation, immunoglobulin class switching, germinal center formation, and dendritic cell maturation — the core machinery of antibody-mediated adaptive immune responses.

The rs1883832 variant sits at position −1 of the CD40 Kozak sequence, a short stretch of nucleotides flanking the AUG start codon that controls how efficiently ribosomes initiate translation. This is a mechanistically precise variant: it does not change what the CD40 protein does, nor does it alter how much CD40 mRNA is transcribed. Instead, it adjusts the efficiency with which existing CD40 mRNA is converted into protein — essentially a molecular rheostat on the immune system's co-stimulatory signal strength.

The Mechanism

The C allele at position −1 creates a stronger Kozak consensus sequence, enabling more efficient ribosomal recognition of the start codon and higher rates of CD40 protein synthesis. The T allele weakens this translational initiation signal²² translational initiation signal
Kozak sequences (GCCACCATGG) guide ribosomes to the start codon; the −1 position is a critical determinant of translation initiation efficiency.

Jacobson et al. (2005) demonstrated this mechanism with multiple independent methods. B cells from individuals with the CT genotype expressed 13.3% less surface CD40 than CC homozygotes; TT individuals showed 39.4% less. In a fibroblast transfection system, T-allele constructs produced 32.2% less CD40 protein than C-allele constructs. An in vitro cell-free transcription/translation system confirmed the effect is post-transcriptional: the T allele produces 15.5% less protein from equivalent mRNA. Crucially, CD40 mRNA levels were identical across genotypes — confirming the mechanism is purely translational. The variant is in strong linkage disequilibrium³³ linkage disequilibrium
LD r²=0.95 with rs4810485 (intronic CD40 variant), meaning they are almost always co-inherited as a single haplotype in Europeans, but their mechanisms are independent: rs1883832 acts at translation, rs4810485 acts via an intronic regulatory element.

The Evidence

Graves' disease is the condition with the strongest and most replicated association. The C allele is the risk allele: Jacobson et al. originally identified this variant in a Graves' disease GWAS⁴⁴ Jacobson et al. originally identified this variant in a Graves' disease GWAS
A Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation. J Clin Endocrinol Metab, 2005, and it has been robustly replicated across ethnicities. A meta-analysis of 40 articles across immune-related diseases⁵⁵ meta-analysis of 40 articles across immune-related diseases
Association between CD40 rs1883832 and immune-related diseases susceptibility: A meta-analysis. Oncotarget, 2017 found the T allele (lower CD40) protective against Graves' disease, especially in Asian populations. Within the Graves' disease subset the protective effect was consistent across Asian (OR 0.700) and Caucasian (OR 0.832) populations. Direction of effect is consistent with the translational mechanism: higher CD40 expression from the C allele amplifies B-cell co-stimulation, promoting thyroid autoantibody production.

Multiple sclerosis and Crohn's disease show the opposite pattern: the minor T allele (lower CD40) is the risk allele for these conditions. In a Spanish cohort of 1,564 MS patients and 1,102 Crohn's patients vs. 2,948 controls⁶⁶ 1,564 MS patients and 1,102 Crohn's patients vs. 2,948 controls
CD40: Novel Association with Crohn's Disease and Replication in Multiple Sclerosis Susceptibility. PLoS One, 2010, the T allele associated with MS (OR 1.12, p=0.025) and Crohn's disease (OR 1.19, p=0.002) but not ulcerative colitis (OR 1.04, p=0.5). This bidirectional association — where C allele promotes antibody-mediated diseases and T allele promotes T-cell-driven inflammatory diseases — is biologically plausible: CD40-CD40L signaling has distinct downstream consequences depending on cellular context. The same meta-analysis confirmed MS risk: OR 1.175 (95% CI 1.093–1.263) across 3,851 MS cases and 4,368 controls.

Coronary heart disease is an emerging third disease axis. The C allele has been associated with elevated soluble CD40L (sCD40L) levels and atherosclerotic risk in multiple case-control studies, with the biological rationale that higher CD40 expression on platelets and endothelial cells amplifies inflammatory signaling in arterial walls. A 2020 review designated rs1883832 as a CD40 SNP for predicting coronary heart disease⁷⁷ designated rs1883832 as a CD40 SNP for predicting coronary heart disease
rs1883832: a CD40 single-nucleotide polymorphism for predicting coronary heart disease in humans. Cardiovasc Res, 2020.

Practical Actions

The actionable implications depend on genotype direction. For CC carriers, the dominant concern is autoantibody-driven autoimmunity — particularly thyroid (Graves' disease), and context-dependent risk for seropositive connective tissue diseases. The variant's strong LD with rs4810485 means the two CD40 findings are nearly identical in most individuals.

For TT carriers, the concern shifts to T-cell-driven inflammatory disease — Crohn's disease and MS risk are modestly elevated. This minority genotype (~7% of Europeans) requires attention to early gastrointestinal and neurological symptoms rather than autoantibody surveillance.

Interactions

rs1883832 is in near-complete linkage disequilibrium (r²=0.95) with the intronic CD40 variant rs4810485. Most individuals who carry rs1883832-C also carry rs4810485-G, and both alleles independently contribute to higher CD40 expression through different mechanisms. The haplotype effect is additive: the combined C-G haplotype drives the highest CD40 surface expression observed in B cells and monocytes.

PTPN22 rs2476601 (R620W) is a mechanistically complementary autoimmune locus: PTPN22 modulates the T-cell activation threshold while CD40 modulates the co-stimulatory signal received by B cells. Carriers of both rs2476601-A and rs1883832-C drive adaptive immune hyperactivation from two independent angles, with additive risk for seropositive autoimmune conditions.

CD40 interacts with the NF-kB pathway via TRAF3 and TRAF6 downstream signaling. TNFAIP3 (A20, rs6920220) is the primary negative regulator of CD40-NF-kB signaling; the rs6920220-G risk allele impairs A20-mediated braking, potentially amplifying the downstream consequences of elevated CD40 expression in CC carriers.

Your blood lipid levels after a meal depend on how efficiently lipoprotein lipase (LPL) — the enzyme that dismantles triglyceride-rich VLDL and chylomicron particles — can do its job. One of LPL's main regulators is ANGPTL3¹¹ ANGPTL3
Angiopoietin-like protein 3, a liver-secreted protein that inhibits LPL in the circulation, slowing triglyceride clearance. The rs2131925 variant sits in a nearby gene (DOCK7) but tags variation in the ANGPTL3 regulatory region that influences how vigorously this brake is applied.

The Mechanism

ANGPTL3 inhibits LPL by binding to its catalytic site, reducing the rate at which triglycerides are hydrolyzed from circulating lipoprotein particles. When ANGPTL3 activity is higher — as the T allele tags — LPL is more suppressed, triglycerides accumulate in the bloodstream, and the downstream HDL-generating byproducts of lipolysis are reduced. ANGPTL3 also inhibits endothelial lipase²² endothelial lipase
an enzyme that clears HDL particles from circulation; inhibiting it would normally preserve HDL, but this is outweighed by the LPL suppression effect, resulting in a net adverse lipid profile in T allele carriers.

The variant is intronic in DOCK7 and does not alter the ANGPTL3 protein sequence directly. It likely acts as a regulatory tag in high linkage disequilibrium with a functional variant that modulates ANGPTL3 expression or post-translational processing in hepatocytes.

The Evidence

The DOCK7/ANGPTL3 locus was first identified as a genome-wide triglyceride signal in Willer et al. 2008³³ Willer et al. 2008
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nature Genetics, 2008 across 8,816 individuals. The Global Lipids Genetics Consortium 2010 paper⁴⁴ Global Lipids Genetics Consortium 2010 paper
Teslovich et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010 in over 100,000 Europeans quantified the effect: each G allele (the protective copy) is associated with 4.94 mg/dL lower fasting triglycerides (95% CI 4.16–5.72, p=9×10⁻⁴³). The association was refined in the 2013 GLGC update⁵⁵ 2013 GLGC update
Willer et al. Discovery and refinement of loci associated with lipid levels. Nature Genetics, 2013 across 188,577 individuals (beta −0.066 log-units, p=3×10⁻⁷⁴).

Beyond lipids, a Finnish case-control study found the T allele was associated with a striking 5-fold increased odds of hypertension in men (OR 5.02, 95% CI 1.40–17.98)⁶⁶ (OR 5.02, 95% CI 1.40–17.98)
Heino & colleagues, Tampere adult population cardiovascular risk study. Lipids Health Dis, 2018, suggesting ANGPTL3-pathway variation may exert direct vascular effects beyond its lipid-lowering influence.

The association replicates across ethnicities: the DOCK7/ANGPTL3 locus was confirmed in African Americans in a transferability study⁷⁷ in a transferability study
Adeyemo et al. Transferability and fine mapping of genome-wide associated loci for lipids across populations. J Clin Lipidol, 2012 of 887 individuals, indicating the signal is not specific to European ancestry.

Practical Actions

For TT carriers — who represent nearly half the European population — the most actionable lever is replacing saturated and refined carbohydrate calories (which promote VLDL synthesis) with omega-3 rich sources that counteract LPL suppression through alternative triglyceride-lowering pathways. High-dose prescription omega-3s (EPA/DHA at 2–4 g/day) achieve clinically meaningful triglyceride reductions through mechanisms that partially bypass the ANGPTL3 brake. Fasting triglyceride monitoring tracks whether compensatory strategies are working.

GT carriers have an intermediate profile and should monitor fasting triglycerides but face less urgent intervention pressure than TT homozygotes.

Interactions

The ANGPTL3/LPL axis overlaps with the ANGPTL4 pathway, which operates tissue- specifically during fasting (particularly in adipose tissue). Variants in ANGPTL4 (e.g., rs2278236) represent a parallel LPL-inhibition mechanism; individuals carrying risk variants at both loci may have compounded triglyceride elevation that exceeds what either variant predicts alone. LPL variants (rs12678919, rs17482753) interact directly at the same enzyme target as ANGPTL3 and may amplify triglyceride effects in compound carriers.

The DIO2 gene encodes type II iodothyronine deiodinase¹¹ type II iodothyronine deiodinase
A selenoprotein enzyme expressed in the brain, pituitary, thyroid, skeletal muscle, and heart that converts the prohormone T4 into the biologically active T3 by removing one iodine atom from the outer ring, the enzyme responsible for locally activating thyroid hormone in the brain, heart, muscle, and pituitary gland. The thyroid itself secretes mostly T4 (thyroxine), which is biologically inert until converted to T3 (triiodothyronine) by deiodinase enzymes in peripheral tissues. DIO2 is the dominant enzyme for this conversion in the central nervous system, where it supplies up to 80% of intracellular T3.

The rs225015 variant sits in the 3' untranslated region (3' UTR)²² 3' untranslated region (3' UTR)
A non-coding stretch of mRNA downstream of the stop codon that regulates mRNA stability, translation efficiency, and response to regulatory proteins like microRNAs of the DIO2 gene on chromosome 14. Unlike the nearby Thr92Ala variant (rs225014), which alters the enzyme protein itself, rs225015 acts at the regulatory level — potentially changing how much DIO2 protein is produced from the gene. This 3' UTR position may affect mRNA stability or microRNA binding³³ mRNA stability or microRNA binding
Changes in the 3' UTR can alter which regulatory microRNAs bind to the transcript, changing its half-life and the efficiency with which ribosomes translate it into protein and thereby modulate tissue-level DIO2 enzyme abundance.

Because DIO2 is also a selenoprotein⁴⁴ selenoprotein
It contains selenocysteine at its catalytic center, an amino acid that requires selenium for incorporation and is essential for the enzyme's deiodination activity, selenium status forms a second layer of influence on DIO2 function beyond genetics — making dietary selenium particularly relevant for anyone with variants that already challenge optimal thyroid hormone conversion.

The Mechanism

The DIO2 gene is located on the minus (reverse) strand of chromosome 14. The rs225015 variant is a G-to-A substitution at position 80,201,236 on the GRCh38 plus strand, corresponding to a C-to-T change in the coding-strand notation used in many publications. The variant affects the 3' UTR of all major DIO2 transcript isoforms NM_000793, NM_013989, and NM_001324462⁵⁵ NM_000793, NM_013989, and NM_001324462
Three splice variants of DIO2 encoding the same catalytic protein with slightly different untranslated regions without altering the protein sequence.

The biological impact of the A allele is not fully characterized at the molecular level — this is a regulatory variant rather than a functional coding change, and its mechanism operates through changes in gene expression rather than enzyme structure. What clinical studies show is that rs225015 genotype is associated with differences in levothyroxine dose requirements and TSH levels⁶⁶ levothyroxine dose requirements and TSH levels
Arici et al. Endocrine Journal 2018 in hypothyroid patients, implying that the variant affects the amount of functional DIO2 enzyme available in tissues.

The Evidence

A 2018 study by Arici et al. in a Turkish hypothyroid cohort⁷⁷ Arici et al. in a Turkish hypothyroid cohort
Endocrine Journal 2018 found that rs225015 genotype was associated with TSH levels and differences in optimal levothyroxine dose, with GG genotype patients requiring lower doses — suggesting these individuals may have higher DIO2 expression and thus more efficient T4-to-T3 conversion, making them more sensitive to exogenous T4. The A allele, by this model, would reduce DIO2 expression and blunt peripheral conversion.

A large UK Biobank analysis of 18,761 levothyroxine-treated patients and 360,534 controls⁸⁸ UK Biobank analysis of 18,761 levothyroxine-treated patients and 360,534 controls
Jensen et al. J Clin Endocrinol Metab 2024 found that the minor A allele showed a nominally significant association with financial dissatisfaction in LT4-treated individuals — a proxy for reduced quality of life that may reflect persistent hypothyroid-like symptoms. However, this study found no significant association with psychological well-being, cognitive function, or cardiovascular risk factors overall. The authors concluded that rs225015, in isolation, does not robustly explain persistent symptoms in levothyroxine-treated patients, echoing findings for the more-studied rs225014 variant in the same gene.

A Danish randomized crossover trial of 45 hypothyroid patients⁹⁹ Danish randomized crossover trial of 45 hypothyroid patients
Carlé et al. Eur Thyroid J 2017 examined combined DIO2 and MCT10 polymorphism burden and found that treatment preference for T3+T4 combination therapy increased with genetic burden — though the study was insufficiently powered to identify effects of rs225015 independently from rs225014 and rs17606253 (MCT10).

Observational data from cardiovascular cohorts suggest additional associations: a study of 290 acute myocardial infarction patients¹⁰¹⁰ 290 acute myocardial infarction patients
Brozaitiene et al. Genet Test Mol Biomarkers 2018 found an association between rs225015 genotype and diabetes mellitus comorbidity, and 168 ischemic stroke patients¹¹¹¹ 168 ischemic stroke patients
Taroza et al. J Stroke Cerebrovasc Dis 2020 were genotyped as part of thyroid axis variant analysis. These associations are exploratory and have not been independently replicated at genome-wide significance.

Practical Actions

For individuals with the AA genotype who are on levothyroxine therapy and experience persistent hypothyroid-like symptoms (fatigue, brain fog, cold intolerance) despite normal TSH, rs225015 could be one contributing factor — particularly when combined with the nearby rs225014 (Thr92Ala) variant. The evidence for rs225015 alone is more limited than for Thr92Ala, and a thorough conversation with an endocrinologist about free T3 levels (not just TSH) is the appropriate next step before considering treatment changes.

Because DIO2 is a selenoprotein, maintaining adequate selenium status is specifically relevant for DIO2 function. The enzyme requires selenocysteine at its catalytic center, and while DIO2 receives prioritized selenium supply during deficiency¹²¹² DIO2 receives prioritized selenium supply during deficiency
Köhrle & Frädrich Free Radic Biol Med 2022, severe selenium deficiency does impair activity. Monitoring serum selenium and considering supplementation with selenomethionine (the organic form with better bioavailability) is a practical step for AA carriers, especially in regions with selenium-poor soils.

Interactions

rs225015 sits in the same gene as rs225014 (DIO2 Thr92Ala), and the two variants are in partial linkage disequilibrium. Studies examining both together suggest additive effects on levothyroxine response: GG/TT haplotypes (both wild-type) show the most efficient T4-to-T3 conversion, while carrying risk alleles at both positions compounds the challenge. However, no published study has characterized the rs225015 + rs225014 haplotype effect with sufficient statistical power to quantify the combined impact precisely.

The MCT10 transporter variant rs17606253 represents a functionally complementary interaction: MCT10 shuttles thyroid hormones into cells, and DIO2 then activates T4 to T3 inside the cell. Variants impairing both transport and conversion create a compound barrier to adequate intracellular T3 that neither variant alone fully predicts. The Carlé 2017 RCT showed 100% treatment preference for T3+T4 in individuals carrying polymorphisms in both genes.

For individuals with AA at rs225015 and CC at rs225014 (the Thr92Ala variant), both the regulatory and catalytic aspects of DIO2 are potentially compromised — this combination may warrant the strongest consideration for combination T3+T4 therapy evaluation.

Every cell in your body replicates approximately 6 billion base pairs of DNA during each division cycle. Before a new DNA strand can be synthesised, a molecular machine called DNA primase¹¹ DNA primase
the enzyme complex that synthesises short RNA primers, providing the 3'-OH ends that DNA polymerase requires to begin copying the template must first lay down short RNA primers at thousands of sites. PRIM1 encodes the small catalytic subunit of this primase — the component that directly synthesises those primers. A single amino acid change at position 5 of the protein, converting aspartate to alanine (p.Asp5Ala), is associated with measurably later age at natural menopause. The cells most vulnerable to primase function are the primary oocytes arrested in meiosis for decades, relying on intact DNA replication and repair machinery to survive.

Note on nomenclature: rs2277339 has two alternate alleles. The G allele (plus-strand, causing p.Asp5Ala) is the common GWAS-significant variant at approximately 11% frequency in Europeans. A second alternate A allele (causing p.Asp5Val) is essentially absent from population databases (≈0% gnomAD); it is not the variant studied in reproductive aging cohorts and is not covered by the interpretations below.

The Mechanism

PRIM1 encodes the 49 kDa catalytic subunit of the heterodimeric primase complex. It directly catalyses RNA primer synthesis de novo — the only step in eukaryotic DNA replication that does not require a pre-existing 3'-OH terminus. The p.Asp5Ala substitution falls within the N-terminal region of the protein, near conserved residues that participate in template binding and catalytic metal coordination. Asp residues at or near the active site of primases are generally involved in coordinating the two divalent metal ions (Mn²⁺ or Mg²⁺) required for nucleotide polymerisation. An Ala substitution at position 5 likely modestly alters the geometry of the catalytic centre rather than abolishing activity outright — consistent with the fact that the G allele is common (11%) and associated with a quantitative shift in menopause timing rather than a Mendelian ovarian failure syndrome.

[Primary oocytes | eggs that have been arrested in the first division of meiosis since before birth, and must wait — sometimes for 40+ years — until recruited into a growing follicle] depend on efficient DNA replication during oocyte growth and on accurate repair of the double-strand breaks introduced intentionally during meiotic recombination. Errors in either process can trigger apoptotic elimination of the affected oocyte, permanently reducing the functional follicle pool. Genome-wide studies of age at natural menopause have consistently over-represented DNA replication and damage-response genes among the top hits²² Genome-wide studies of age at natural menopause have consistently over-represented DNA replication and damage-response genes among the top hits
Ruth et al. 2021 mapped 290 determinants of ovarian ageing, the majority converging on the DNA damage response, which makes the primase gene a biologically coherent candidate.

Telomere maintenance is a second relevant pathway. Telomeres are replicated by a specialised mechanism that still requires primase activity for lagging-strand synthesis of the complementary strand. Shortened or dysfunctional telomeres in granulosa cells and oocytes accelerate follicle loss; a subtle impairment in primase catalysis could disproportionately affect the telomere-adjacent sequences where replication efficiency is already reduced.

The Evidence

The primary evidence comes from two large genome-wide association studies.

Stolk et al. 2012³³ Stolk et al. 2012
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nature Genetics, 44:260–268 conducted a meta-analysis of 22 GWAS including 38,968 European women, with replication in up to 14,435 additional women. The study identified 13 novel genome-wide significant loci for age at natural menopause; PRIM1 was one of eight candidate genes explicitly implicated in DNA damage response and repair. The enrichment of DNA-repair loci was statistically striking — PRIM1, TLK1, HELQ, EXO1, UIMC1, FAM175A, FANCI, and POLG all reached genome-wide significance, pointing to a shared biological bottleneck in oocyte DNA maintenance as a key determinant of ovarian lifespan.

Ruth et al. 2021⁴⁴ Ruth et al. 2021
Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 596:393–397 extended this work to approximately 200,000 women of European ancestry, identifying 290 genetic determinants of ovarian ageing. PRIM1 rs2277339 was among the top coding missense variants in that study, with the G allele associated with approximately 0.354 years (about 18 weeks) later natural menopause per allele copy. Women with the highest polygenic burden for late menopause reached a risk profile comparable to carriers of FMR1 premutations — a known cause of premature ovarian insufficiency — illustrating how multiple modest GWAS loci accumulate to clinically meaningful shifts.

A maternal genotyping study by Chan et al. 2023⁵⁵ maternal genotyping study by Chan et al. 2023
Maternal polymorphisms of meiosis and DNA damage repair genes and fetal chromosomal stability. J Perinat Med, 51:1082–1096 examined rs2277339 alongside seven other DNA repair variants in 571 women carrying foetuses with chromosomal abnormalities versus 811 controls. Significant genotype differences were found for PRIM1 rs2277339 (p=0.008) specifically in the advanced maternal age subgroup with fetal aneuploidy — suggesting that PRIM1 primase function may influence not only the timing of follicle depletion but also the fidelity of meiotic chromosome segregation in ageing oocytes.

Population specificity: a Sanger sequencing study of 192 Chinese women with primary ovarian insufficiency⁶⁶ Sanger sequencing study of 192 Chinese women with primary ovarian insufficiency
Wang et al. 2016, Reprod Biomed Online found no coding PRIM1 mutations contributing to POI in that cohort, and prior GWAS signals at rs2277339 did not replicate in East Asian women. This likely reflects that rs2277339 is a tag SNP in linkage disequilibrium with the causal variant in European-ancestry populations but not in East Asian LD blocks — rather than a true absence of PRIM1 biology in non-European ovaries. The G allele frequency in East Asian populations (~22%) is actually higher than in Europeans (~10.5%), reinforcing that frequency alone cannot distinguish causal from tag SNPs.

Practical Actions

Each G allele at rs2277339 shifts expected menopause onset approximately 0.35 years (about 18 weeks) later in the population-average sense. For TT individuals — by far the most common genotype (~78% of people) — menopause timing from this locus is at the baseline. For TG carriers (~20% of people), the G allele provides a modest delay. The GG genotype (~1.4%) provides the greatest average delay.

The clinical implication runs in the opposite direction from most risk-oriented SNPs: this variant, in its G-allele form, represents a slight protective signal for ovarian lifespan. For TT individuals without G-allele protection, ovarian reserve monitoring from a DNA-repair perspective follows standard clinical guidance rather than an elevated-risk protocol.

Because PRIM1 primase function is linked to DNA replication accuracy during oocyte growth phases, interventions that reduce oxidative DNA damage in the ovary are mechanistically relevant across all genotypes — but are most directly applicable to the TT baseline group who lack the extended-primase-efficiency benefit conferred by the G allele.

Interactions

PRIM1 rs2277339 operates within a network of DNA-damage-response and replication loci that were all simultaneously identified in the Stolk 2012 and Ruth 2021 GWAS. The most relevant partners in the GeneOps database are:

rs10183486 (TLK1) — Tousled-like kinase 1 phosphorylates the Asf1 histone chaperone during DNA replication and repair. TLK1 and PRIM1 work in adjacent stages of the same replication fork: PRIM1 synthesises the primer, and TLK1-Asf1 packages the newly synthesised DNA into chromatin. Women carrying T alleles at rs10183486 (earlier menopause risk) and also lacking G alleles at rs2277339 (baseline primase efficiency) may have a compound disadvantage in oocyte DNA maintenance, though no published analysis has formally tested this combination.

rs16991615 (MCM8) — MCM8 is a helicase essential for homologous recombination repair of meiotic double-strand breaks. Like PRIM1, it emerged from the same GWAS wave and is associated with age at natural menopause and AMH levels. The MCM8–PRIM1 pair represents convergent failure points in the replication–repair continuum.